scholarly journals Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States

2016 ◽  
Vol 6 (7) ◽  
pp. 996-1003 ◽  
Author(s):  
Rishi Agarwal ◽  
Arun Sendilnathan ◽  
Nabeela Iffat Siddiqi ◽  
Shuchi Gulati ◽  
Abhimanyu Ghose ◽  
...  
Keyword(s):  
United States ◽  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Care Center ◽  
Tertiary Care ◽  
The United States ◽  
Tertiary Care Center ◽  
Tract Cancer

Advanced biliary tract cancer: Experience with ABC-02 regimen in a tertiary care center in the United States.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15624-e15624
Author(s):  
Rishi Agarwal ◽  
Nabeela Iffat Siddiqi ◽  
Shuchi Gulati ◽  
Arun Sendilnathan ◽  
Changchun Xie ◽  
...  
Keyword(s):  
United States ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Care Center ◽  
Tertiary Care ◽  
The United States ◽  
Tertiary Care Center ◽  
Tract Cancer ◽  
Cancer Experience

Clinical outcomes and prognostic factors of adjuvant treatment in resectable biliary tract cancer.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 370-370 ◽  
Author(s):  
Ji Hyung Hong
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Biliary Tract ◽  
Adjuvant Treatment ◽  
Biliary Tract Cancer ◽  
Treatment Modality ◽  
Perineural Invasion ◽  
Histologic Grade ◽  
Survival Outcomes ◽  
Tract Cancer

370 Background: The survival outcomes and prognostic factors of adjuvant treatment after resection for biliary tract cancer (BTC) has not been clearly established. We analyzed the clinical outcomes and prognostic factors of patients with resected BTCs between adjuvant treatment and non-adjuvant treatment group. Methods: A total 189 patients of BTC were treated with surgery followed by adjuvant chemotherapy or concurrent chemoradiotherapy between Jan. 2008 and Jan. 2013. We retrospectively analyzed the clinical characteristics and recurrence and survival outcomes with following variables: histologic grade, resected margin status, lymphatic/vascular/perineural invasion, T and N stage, treatment modality. Results: Median age at diagnosis was 64 years (range: 32-85). Of the total 189 patients, R0 resection was done in 152 patients (80.4%). Among the 73 patients with adjuvant treatment, forty-one patients (21.6%) were treated with adjuvant 5-FU based systemic chemotherapy and 31 patients with chemoradiotherapy (16.5%). Recurrence rate were 39.7%. Median disease free survival (DFS) time was 58.1 months (95% CI, 38.9-77.3) and median overall survival (OS) time was 87.8 months (95% CI, 79.5-96.0). Adjuvant treatment showed the tendency to improve DFS with 39.0 months (95% CI, 8.9-69.1) in the adjuvant group compared with 57.0 months (95% CI, 39.5-74.5) in the non-adjuvant group, however, without statistical significance (p=0.113). Between the recurrent and non-recurrent group, perineural invasion, lymphatic invasion and poorly differentiated histology showed statistical significant difference, respectively (65.3% vs 35% ; p <.001, 28% vs 14.9% ; p = .028, and 8.1% vs 7.1% ; p = .011). Presence of perineural invasion showed association with RFS (HR= 1.543; 95% CI 1.133-2.102, p=.006). There was no other significant correlation in R1 resection, poor histologic grade, lymphatic and vascular invasion, chemotherapy regimen, and treatment modality with survival outcome. Conclusions: Perineural invasion could be a potential prognostic factor for recurrence. Further prospective study should be warranted to confirm this data.

scholarly journals In-hospital mortality after resection of biliary tract cancer in the United States

HPB ◽  
2010 ◽  
Vol 12 (1) ◽  
pp. 62-67 ◽  
Author(s):  
James E. Carroll Jr ◽  
Zachary M. Hurwitz ◽  
Jessica P. Simons ◽  
James T. McPhee ◽  
Sing Chau Ng ◽  
...  
Keyword(s):  
United States ◽  
Hospital Mortality ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
The United States ◽  
Tract Cancer

Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer

2017 ◽  
Vol 103 (4) ◽  
pp. 345-352
Author(s):  
Jeong Il Yu ◽  
Hee Chul Park ◽  
Do Hoon Lim ◽  
Joon Oh Park ◽  
Young Suk Park ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Surgical Resection ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Chemotherapy Regimen ◽  
Significant Prognostic Factor ◽  
Free Survival ◽  
Tract Cancer ◽  
Locally Recurrent

Purpose The purpose of this study was to investigate the clinical outcomes and prognostic factors of concurrent chemoradiotherapy (CCRT) for locally recurrent biliary tract cancer (BTC) after curative surgical resection. Methods We performed a retrospective cohort study of patients with locally recurrent BTC treated with CCRT between October 2004 and December 2013. The study included and analyzed 42 patients with a history of curative-intent surgical resection of confirmed adenocarcinoma originating from the biliary tract. Results The median time to recurrence after surgery was 16.1 months (range, 4.5-77.8 months). Median follow-up after CCRT was 26.9 months (range, 5.2-81.9) with no grade 3 or higher gastrointestinal toxicities. Analysis of the first site of failure showed local progression (LP) developed in 20 patients (47.6%); among these, 16 (38.1%) had isolated LP. The median values were 15.8 months (range, 1.7-81.7) for LP-free survival (LPFS), 10.6 months (range, 1.7 - 81.7) for progression-free survival (PFS) and 41.2 months (range, 5.2-81.9) for overall survival (OS). Multivariate analysis showed that the level of pre-CCRT carbohydrate antigen (CA) 19-9 and the chemotherapy regimen were significant prognostic factors for LPFS and PFS; pT stage was the only significant prognostic factor for OS. Conclusions CCRT for locally recurrent BTC showed promising outcomes as a salvage modality, but LP was still frequent. The pre-CCRT CA 19-9 level and the chemotherapy regimen were prognostic factors for LPFS and PFS.

Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States

2020 ◽  
Vol 82 (4) ◽  
pp. 1023-1024 ◽  
Author(s):  
Hasan Khosravi ◽  
Sophia Zhang ◽  
Alyce M. Anderson ◽  
Laura K. Ferris ◽  
Sonal Choudhary ◽  
...  
Keyword(s):  
United States ◽  
Care Center ◽  
Tertiary Care ◽  
The United States ◽  
Tertiary Care Center ◽  
Drug Survival ◽  
Insurance Approval

Biliary Tract Cancer

2017 ◽  
Author(s):  
Jill Koshiol ◽  
Catterina Ferreccio ◽  
Susan S. Devesa ◽  
Juan Carlos Roa ◽  
Joseph F. Fraumeni
Keyword(s):  
United States ◽  
Gallbladder Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Bile Ducts ◽  
The United States ◽  
Ampulla Of Vater ◽  
Biliary Tract Cancers ◽  
Tract Cancer ◽  
Extrahepatic Bile Ducts

Biliary tract cancers encompass tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. In the United States, biliary tract cancer is the fifth most common malignant neoplasm of the digestive tract, accounting for about 3,700 deaths per year. The gallbladder is the primary subsite for 40% of biliary tract cancers, followed by the extrahepatic bile ducts (33%), ampulla of Vater (20%), and unspecified subsite (8%). Gallbladder cancer occurs twice as often in women than men, while other biliary tumors are more common in men. Risk of gallbladder cancer is elevated in Amerindians, including the Pima Indians in the United States and the Mapuches in Chile, and in certain Hispanic populations. While a significant fraction of these tumors are related to underlying gallstones (cholelithiasis), information on other risk factors is limited, due to the rarity of the tumors, the often rapidly fatal course, and small number of epidemiologic studies.

Demographics and disease processes of patients seeking second medical hematology/oncology opinions at a tertiary care center in the United States

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16018-16018
Author(s):  
K. K. Curtis ◽  
D. W. Northfelt
Keyword(s):  
United States ◽  
Clinical Benefit ◽  
Care Center ◽  
Tertiary Care ◽  
Case Series ◽  
The United States ◽  
Lymphocytic Leukemia ◽  
Tertiary Care Center ◽  
Data Set ◽  
Related Information

16018 Background: Second opinions (SO) are common in medical practice. Aside from case series, little evidence exists to demonstrate a clinical benefit associated with SO. Lack of relevant data limits knowledge of numbers of patients, diseases, and motivations of SO seekers. Within the field of medical hematology/oncology (H/O), no specific demographic data are available to characterize patients seeking SO in the United States. Methods: To typify such patients at Mayo Clinic in Arizona (MCA), we recorded demographic and disease-related information for patients seeking these evaluations over a six month period from 1/1 through 6/30/05. Results: A total of 683 patients contacted MCA for medical H/O SO over the 6 month study period. A complete set of demographic and disease-related information was obtained from 655 patients; the remainder were excluded from the data set. Demographically, the majority of patients were female (53%), married (66%), and lived nearby (i.e., from Arizona-58%, or bordering state-22%). Average age was 62.3 years. Among oncologic diagnoses, the majority of patients (60% of 374 reported oncologic diagnoses) stated a diagnosis of breast, lung, colorectal, pancreatic or prostate cancer. Approximately 1/3 of patients had metastatic disease at the time they sought evaluation at MCA. There were 278 patients seeking evaluation for hematologic abnormalities, with the majority (160 patients, 58%) seeking evaluation for non-malignant conditions. Of those with malignancies, lymphoma (including Hodgkin and non-Hodgkin) was the most common (45%), followed by multiple myeloma (21%) and chronic lymphocytic leukemia (15%). Conclusions: This study provides insight into demographics and disease processes of patients seeking medical H/O SO at a tertiary care center in the United States. Although no definite conclusions can be drawn about motivations for seeking H/O SO, future research should examine patient motivation to better understand factors leading to this behavior. Given a lack of evidence for clinical benefit associated with SO seeking, and its potential costliness, better knowledge of demographic and motivational factors may allow for a more constructive approach to be taken toward the needs of SO seekers. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document